Median Technologies secures €19 million from the EIB to support its expansion
Median Technologies, a leading player in AI-based software solutions for cancer screening, announces a €19 million funding from the European Investment Bank. This financial support represents the first installment of an agreement totaling €37.5 million. The company aims to accelerate the commercialization of its key product, eyonis® LCS, in the United States and Europe.
A Major Breakthrough in the Development of eyonis® LCS
The €19 million funding granted on October 21, 2025, marks the first step in an extensive partnership signed with the EIB, which could reach €37.5 million. This initiative aims to support the commercial launch of eyonis® LCS, a software dedicated to the early detection of lung cancer, in both the North American and European markets. Median Technologies aims to address a significant medical need by optimizing diagnostic efficiency through artificial intelligence. According to CEO Fredrik Brag, « this funding will accelerate deployment in the United States and Europe, and expand the eyonis® range to new oncology indications. » This new initiative comes in the context of high demand for innovative solutions in medical imaging, where early diagnosis is crucial.
Strong Financial Structuring for Median Technologies
This financing, structured into three installments (19, 8.5, and 10 million euros), adds to a recent capital increase of 23.9 million euros, significantly strengthening the group's cash reserves. Additionally, the repayment of 20.7 million euros from the first tranche of a previous EIB loan contracted in 2019 was completed on October 17, 2025. Median now announces having solid financial visibility until the fourth quarter of 2026, a crucial factor considering the investments needed to obtain 510(k) and CE regulatory approvals for market access. Besides the immediate cash reserves, the company has additional potential through the exercise of stock warrants amounting to up to 51.7 million euros. The Tranche A loan spans six years, carries an interest rate of 5%, and includes the issuance of 3,403,164 stock warrants.
Short- and Medium-Term Strategic Perspectives and Challenges
Median Technologies' pipeline is expanding and strengthening with this influx of capital, as it approaches major regulatory milestones expected as early as the first quarter of 2026 for eyonis® LCS. The investment from the European Investment Bank represents a strong vote of confidence in the company's ability to achieve these milestones at a time when the demand for early and AI-assisted diagnostic solutions is on the rise. The expansion of the eyonis® solution portfolio to include other oncological pathologies is also being considered, in line with the strategy announced by management. The upcoming release of the half-year results, expected on October 23, 2025, will be closely watched by the financial community, eager to assess the progress of the platform's commercial deployment and cash flow developments, amid a broader consolidation in the medtech sector.
This content has been automatically translated using artificial intelligence. While we strive for accuracy, some nuances may differ from the original French version.
